Johnson & Johnson (JNJ)
-NYSE 88.09 
0.64(0.73%) 18 May 04:02 SGT|After Hours
:
88.38 0.29 (0.33%) 18 May 06:31 SGT
| Prev Close: | 87.45 |
|---|
| Open: | 87.45 |
|---|
| Bid: | 87.95 x 300 |
|---|
| Ask: | 88.30 x 300 |
|---|
| 1y Target Est: | 86.50 |
|---|
| Beta: | 0.48 |
|---|
| Next Earnings Date: | 15-Jul-13 |
|---|
| Day's Range: | 87.41 - 88.20 |
|---|
| 52wk Range: | 61.71 - 88.20 |
|---|
| Volume: | 11,439,498 |
|---|
| Avg Vol (3m): | 9,721,630 |
|---|
| Market Cap: | 247.43B |
|---|
| P/E (ttm): | 23.92 |
|---|
| EPS (ttm): | 3.68 |
|---|
| Div & Yield: | 2.64 (3.10%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Medical Devices companiesAP(Sat, 18 May)
- Final Glance: Pharmaceuticals companiesAP(Sat, 18 May)
- Midday Glance: Pharmaceuticals companiesAP(Sat, 18 May)
- Midday Glance: Medical Devices companiesAP(Sat, 18 May)
- J&J's DePuy to end 2 hip replacement systemsAP(Sat, 18 May)
- Early Glance: Medical Devices companiesAP(Fri, 17 May)
- Early Glance: Pharmaceuticals companiesAP(Fri, 17 May)
- South Korea's Celltrion sale seen slow-going as sceptics emergeReuters(Wed, 15 May)
- Vivus names 2 new directors to its boardAP(Mon, 13 May)
- Dendreon says competition hurt 1Q Provenge salesAP(Fri, 10 May)
- Pipeline Setback for IdenixZacks(Fri, 8 Feb)
- Elan Beats on Sales, Loses TysabriZacks(Fri, 8 Feb)
- Kalydeco Funding Cleared in IrelandZacks(Thu, 7 Feb)
- Bayer, J&J Collaborate with PortolaZacks(Thu, 7 Feb)
- LRY Unveils $55M ProjectZacks(Wed, 6 Feb)
Key Statistics
| Forward P/E (1 yr): | 15.24 |
|---|
| P/S (ttm): | 3.58 |
|---|
| Ex-Dividend Date: | 23-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.41 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.39 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 2.55 |
|---|
Business Summary
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
View More